论文部分内容阅读
血管内栓塞的溶血疗法,自七十年代后有很大进展,目前国内外已应用的溶栓剂如链激素和尿激素都获得较满意效果,冠状动脉内注射链激酶,血管再通率达百分之八十一,静脉注射尿激酶,血管再通率可达百分之七十九。美国有关研究单位近年来先后开展了新的溶栓剂——应用DNA重组技术生产的人组织型纤维蛋白溶酶原激活剂(TPA)的动物实验和临床研究,取得了初步可喜的结果。
Hemolytic therapy of intravascular embolization has made great progress since the seventies. At present, thrombolytic agents such as streptokinase and urinary hormone have been used both at home and abroad to obtain satisfactory results. Injectable streptokinase in coronary artery, the rate of vascular recanalization Eighty-one percent of patients received intravenous urokinase and the blood recanalization rate reached seventy-nine percent. In recent years, relevant research institutes in the United States have carried out animal experiments and clinical studies on new thrombolytic agents - human tissue-type plasminogen activator (TPA) produced by DNA recombination technology. Preliminary and encouraging results have been achieved.